Neuberger Berman Group
AIMT

Neuberger Berman Group’s Aimmune Therapeutics AIMT Stock Holding History

Neuberger Berman Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-42,525
Closed -$613K – 1639
2020
Q1 		$613K Buy
+42,525
New +$1.09M ﹤0.01% 1197

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Neuberger Berman Group's AIMT Position: Q2 2020 in Review

Neuberger Berman Group sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 42,525 shares — an estimated $613K sold.

Neuberger Berman Group first reported a position in AIMT in Q1 2020 and held it in 1 quarter. The position peaked at $613K in Q1 2020. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Neuberger Berman Group reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Neuberger Berman Group sold 42,525 Aimmune Therapeutics shares in Q2 2020, an estimated $613K.
  • Neuberger Berman Group first reported a position in Aimmune Therapeutics in Q1 2020 and held it in 1 quarter.
  • Neuberger Berman Group's Aimmune Therapeutics position peaked at $613K in Q1 2020.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Neuberger Berman Group's 13F filing for Q2 2020, filed 13 Aug 2020.